Global Lupus Erythematosus Treatment Market

Lupus Erythematosus Treatment Comprehensive Study by Route of Administration (Oral, Intravenous, Subcutaneous), Treatment (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic and Immunosuppressive Drugs, Disease-Modifying Anti-Rheumatic Drugs, Monoclonal Antibodies, Anticoagulants, Biologics, Others), End Use (Hospital, Specialty Clinics)

Lupus Erythematosus Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Lupus Erythematosus Treatment
In the past years, the prognosis for people with chronic lupus erythematosus has greatly increased. Faster diagnosis, renal dialysis and transplantation, and improved general care (such as blood pressure control and osteoporosis treatment) have also played a part. In Lupus Erythematosus patients, osteoporosis is a common concern. They have a high risk of bone loss and fractures due to disease activity, immobility, and, most importantly, the use of glucocorticoids. Age, gender, osteoporosis, low BMI, fall risk, low vitamin D levels, and lifestyle are all risk factors. SLE affects almost all of the body's organs and systems. Glucocorticoids, antimalarials, traditional synthetic immunosuppressive medications, and biologic treatments are among the treatment options for SLE.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Lupus Erythematosus Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc (United Kingdom), ImmuPharma LLC (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland), Anthera Pharmaceuticals Inc. (United States), Bristol-Myers-Squibb Company (United States), Eli Lilly and Company (United States), Pfizer Inc. (United States), Merck & Co. (United States), Lycera Corporation (United States) and Mylan N.V. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sanofi S.A. (France), Aurinia Pharmaceuticals Inc. (Canada), Sandoz International GmbH (Germany), Novartis AG (Switzerland), Bayer AG (Germany), Bio-Rad Laboratories Inc. (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Lupus Erythematosus Treatment market by and Region.



On the basis of geography, the market of Lupus Erythematosus Treatment has been segmented into . If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Lupus Erythematosus Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment, the sub-segment i.e. Antimalarial Drugs will boost the Lupus Erythematosus Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Use, the sub-segment i.e. Hospital will boost the Lupus Erythematosus Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Healthcare Infrastructure Due to Pandemic and Emergence of Fast and Efficient Techniques

Market Growth Drivers:
Prevalence of SLE Cases Across the Globe, Rising Healthcare Awareness and Technical Progress Corticoid Applications

Challenges:
Regulatory Approval and Lack of Trained Professionals

Restraints:
Skewed Player Distribution

Opportunities:
Low Penetration in Emerging Regions Particularly Asia

Market Leaders and their expansionary development strategies
In April, 2021 - Sorrento Enters into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics, this Acquisition will Add ACEA’s Systemic Lupus Erythematosus and The Ultra-Orphan Indication of Hairy Cell Leukemia Capabilities to Sorrento’s Therapeutics Portfolio.
In December, 2020 - GlaxoSmithKline Declared FDA Approval for BENLYSTA (belimumab), the First Chronic Disease Treatment for Adult Patients with Lupus Nephritis (LN) Who Are Undergoing Regular Therapy. The Approval Covers Both the Intravenous and Subcutaneous Formulations of The Treatment.
United States, Food and Drug Administration “Systemic Lupus Erythematosus - Developing Medical Products for Treatment” - Provision Refers to Approval, Inspection and Dosage Limitations of Lupus Erythematosus Drugs across the United States, FDA limits the usage to licensed prescription holders only. Any New Entrant is Required to have a Regulatory Clearance form FDA.

Key Target Audience
Lupus Erythematosus Drug Manufactures, New Entrants and Investors, Lupus Erythematosus Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Route of Administration
  • Oral
  • Intravenous
  • Subcutaneous

By Treatment
  • Antimalarial Drugs
  • Non-Steroidal Anti-Inflammatory Drugs
  • Cytotoxic and Immunosuppressive Drugs
  • Disease-Modifying Anti-Rheumatic Drugs
  • Monoclonal Antibodies
  • Anticoagulants
  • Biologics
  • Others

By End Use
  • Hospital
  • Specialty Clinics

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Prevalence of SLE Cases Across the Globe
        • 3.2.2. Rising Healthcare Awareness
        • 3.2.3. Technical Progress Corticoid Applications
      • 3.3. Market Challenges
        • 3.3.1. Regulatory Approval
        • 3.3.2. Lack of Trained Professionals
      • 3.4. Market Trends
        • 3.4.1. Growing Healthcare Infrastructure Due to Pandemic
        • 3.4.2. Emergence of Fast and Efficient Techniques
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global Lupus Erythematosus Treatment, by Route of Administration, Treatment and End Use (value) (2018-2023)
      • 5.1. Introduction
      • 5.2. Global Lupus Erythematosus Treatment (Value)
        • 5.2.1. Global Lupus Erythematosus Treatment by: Route of Administration (Value)
          • 5.2.1.1. Oral
          • 5.2.1.2. Intravenous
          • 5.2.1.3. Subcutaneous
        • 5.2.2. Global Lupus Erythematosus Treatment by: Treatment (Value)
          • 5.2.2.1. Antimalarial Drugs
          • 5.2.2.2. Non-Steroidal Anti-Inflammatory Drugs
          • 5.2.2.3. Cytotoxic and Immunosuppressive Drugs
          • 5.2.2.4. Disease-Modifying Anti-Rheumatic Drugs
          • 5.2.2.5. Monoclonal Antibodies
          • 5.2.2.6. Anticoagulants
          • 5.2.2.7. Biologics
          • 5.2.2.8. Others
        • 5.2.3. Global Lupus Erythematosus Treatment by: End Use (Value)
          • 5.2.3.1. Hospital
          • 5.2.3.2. Specialty Clinics
    • 6. Lupus Erythematosus Treatment: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2023)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. GlaxoSmithKline plc (United Kingdom)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. ImmuPharma LLC (United Kingdom)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. F. Hoffmann-La Roche Ltd. (Switzerland)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. Anthera Pharmaceuticals Inc. (United States)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. Bristol-Myers-Squibb Company (United States)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. Eli Lilly and Company (United States)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. Pfizer Inc. (United States)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. Merck & Co. (United States)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. Lycera Corporation (United States)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. Mylan N.V. (United States)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
    • 7. Global Lupus Erythematosus Treatment Sale, by Route of Administration, Treatment and End Use (value) (2025-2030)
      • 7.1. Introduction
      • 7.2. Global Lupus Erythematosus Treatment (Value)
        • 7.2.1. Global Lupus Erythematosus Treatment by: Route of Administration (Value)
          • 7.2.1.1. Oral
          • 7.2.1.2. Intravenous
          • 7.2.1.3. Subcutaneous
        • 7.2.2. Global Lupus Erythematosus Treatment by: Treatment (Value)
          • 7.2.2.1. Antimalarial Drugs
          • 7.2.2.2. Non-Steroidal Anti-Inflammatory Drugs
          • 7.2.2.3. Cytotoxic and Immunosuppressive Drugs
          • 7.2.2.4. Disease-Modifying Anti-Rheumatic Drugs
          • 7.2.2.5. Monoclonal Antibodies
          • 7.2.2.6. Anticoagulants
          • 7.2.2.7. Biologics
          • 7.2.2.8. Others
        • 7.2.3. Global Lupus Erythematosus Treatment by: End Use (Value)
          • 7.2.3.1. Hospital
          • 7.2.3.2. Specialty Clinics
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. Lupus Erythematosus Treatment: by Route of Administration(USD Million)
    • Table 2. Lupus Erythematosus Treatment: by Treatment(USD Million)
    • Table 3. Lupus Erythematosus Treatment: by End Use(USD Million)
    • Table 4. Company Basic Information, Sales Area and Its Competitors
    • Table 5. Company Basic Information, Sales Area and Its Competitors
    • Table 6. Company Basic Information, Sales Area and Its Competitors
    • Table 7. Company Basic Information, Sales Area and Its Competitors
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Lupus Erythematosus Treatment: by Route of Administration(USD Million)
    • Table 15. Lupus Erythematosus Treatment: by Treatment(USD Million)
    • Table 16. Lupus Erythematosus Treatment: by End Use(USD Million)
    • Table 17. Research Programs/Design for This Report
    • Table 18. Key Data Information from Secondary Sources
    • Table 19. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Lupus Erythematosus Treatment: by Route of Administration USD Million (2018-2023)
    • Figure 5. Global Lupus Erythematosus Treatment: by Treatment USD Million (2018-2023)
    • Figure 6. Global Lupus Erythematosus Treatment: by End Use USD Million (2018-2023)
    • Figure 7. Global Lupus Erythematosus Treatment share by Players 2023 (%)
    • Figure 8. Global Lupus Erythematosus Treatment share by Players (Top 3) 2023(%)
    • Figure 9. Global Lupus Erythematosus Treatment share by Players (Top 5) 2023(%)
    • Figure 10. BCG Matrix for key Companies
    • Figure 11. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 12. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
    • Figure 13. ImmuPharma LLC (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 14. ImmuPharma LLC (United Kingdom) Revenue: by Geography 2023
    • Figure 15. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
    • Figure 16. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
    • Figure 17. Anthera Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 18. Anthera Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
    • Figure 19. Bristol-Myers-Squibb Company (United States) Revenue, Net Income and Gross profit
    • Figure 20. Bristol-Myers-Squibb Company (United States) Revenue: by Geography 2023
    • Figure 21. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
    • Figure 22. Eli Lilly and Company (United States) Revenue: by Geography 2023
    • Figure 23. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 24. Pfizer Inc. (United States) Revenue: by Geography 2023
    • Figure 25. Merck & Co. (United States) Revenue, Net Income and Gross profit
    • Figure 26. Merck & Co. (United States) Revenue: by Geography 2023
    • Figure 27. Lycera Corporation (United States) Revenue, Net Income and Gross profit
    • Figure 28. Lycera Corporation (United States) Revenue: by Geography 2023
    • Figure 29. Mylan N.V. (United States) Revenue, Net Income and Gross profit
    • Figure 30. Mylan N.V. (United States) Revenue: by Geography 2023
    • Figure 31. Global Lupus Erythematosus Treatment: by Route of Administration USD Million (2025-2030)
    • Figure 32. Global Lupus Erythematosus Treatment: by Treatment USD Million (2025-2030)
    • Figure 33. Global Lupus Erythematosus Treatment: by End Use USD Million (2025-2030)
    List of companies from research coverage that are profiled in the study
    • GlaxoSmithKline plc (United Kingdom)
    • ImmuPharma LLC (United Kingdom)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Anthera Pharmaceuticals Inc. (United States)
    • Bristol-Myers-Squibb Company (United States)
    • Eli Lilly and Company (United States)
    • Pfizer Inc. (United States)
    • Merck & Co. (United States)
    • Lycera Corporation (United States)
    • Mylan N.V. (United States)
    Additional players considered in the study are as follows:
    Sanofi S.A. (France) , Aurinia Pharmaceuticals Inc. (Canada) , Sandoz International GmbH (Germany) , Novartis AG (Switzerland) , Bayer AG (Germany) , Bio-Rad Laboratories Inc. (United States) , Others
    Select User Access Type

    Key Highlights of Report


    Apr 2024 225 Pages 55 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

    Request Sample Pages

    Budget constraints? Get in touch with us for special pricing


    Check Discount Now
    Global Lupus Erythematosus Treatment Market Quantitative research analysis
    Global Lupus Erythematosus Treatment Market Qualitative Industry Analysis
    DOWNLOAD SAMPLE PDF

    Talk to Our Experts

    Want to Customize Study?


    "We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

    Make an Enquiry Now

    Frequently Asked Questions (FAQ):

    The standard version of the report profiles players such as GlaxoSmithKline plc (United Kingdom), ImmuPharma LLC (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland), Anthera Pharmaceuticals Inc. (United States), Bristol-Myers-Squibb Company (United States), Eli Lilly and Company (United States), Pfizer Inc. (United States), Merck & Co. (United States), Lycera Corporation (United States) and Mylan N.V. (United States) etc.
    The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
    "Growing Healthcare Infrastructure Due to Pandemic " is seen as one of major influencing trends for Lupus Erythematosus Treatment Market during projected period 2023-2030.
    The Lupus Erythematosus Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

    Know More About Global Lupus Erythematosus Treatment Market Report?

    Have a Query? Click Here

    Other Related Reports

    Vesicoureteral Reflux Treatment Comprehensive Study by Type (Primary VUR, Secondary VUR), Treatment (Medicinal Treatment (Antibiotics and Anticholinergics), Minimally Invasive Surgical Treatment), En...
    $ 3350
    Esophageal Disorders Treatment Comprehensive Study by Application (Hospital Pharmacies, Retail Pharmacy, Drug Stores, Online), Drug Type (Antacids, H2 Blockers, Proton Pump Inhibitors, Prokinetics, O...
    $ 3650
    Autism Treatment Comprehensive Study by Type (Asperger Syndrome, Pervasive Developmental Disorder, Others), Drugs (SSRIs, Anti-Convulsant, Others), Treatment (Aba, Hyperbaric Oxygen Therapy, Others) ...
    $ 3500
    Sound Therapy Comprehensive Study by Type (Guided Meditation, Neurologic Music Therapy, Bonny Method, Others), Application (Tinnitus & Hearing, Children & Learning, Emotional & Stress Relief, Brain P...
    $ 3650
    Rare hematology disorders Comprehensive Study by Type (Rare blood cancers, Platelet based disorders, Plasma disorders, Myeloproliferative disorders, Genetic hematology disorders), Route of Administra...
    $ 3650
    Astigmatism Treatment Comprehensive Study by Type (Eyeglasses, Contact lens, Orthokeratology, Laser surgeries, LASIK(Laser- Assisted In situ Keratomileusis), LASEK(Laser- Assisted Subepithelial Kerat...
    $ 3750